MyShare
USLSEAU KLSEHKSG
user
Profile login
Help Center Ask Forum Keyboard Shortcuts

home

BVXP.LSE | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

Assets: cash current-assets inventory receivables investments invested ppe nta assets net-debt working-capital liabilities long-term-debt accounts-payable non-current-liabilities

Income sheet sales operations-income gross-profit | expenses marketing r-and-d income-before-tax tax income net-income interest-income ebit leases interest earnings

Key Financials BVXP

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
symbollastchange%chngnamemcapsectorwiki
BVXP Bioventix 0.245B Healthcare

symbolprev.closerangecharttargetpercentperiodmonthsduerating
 A  BVXP 4450.00 0,0.411,0.252,0.963,0.411 4269.28,4187.17,4300.47,4477.81,4709.34,4908.35,4837.42,4798.01,4600.97,4532.00,4396.53,4470.42,4592.90,4580.00,4475.00 4579.67-5057.78 8.29% 267,114,267 5.1 Jan 5-Sep 28 67.06%

1 BVXP LSE

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The impact shows the impact of the figure on the share price forecast. Sometimes the impact of an increasing beneficial figure may still be downwards when the increase was smaller than expected. The over figure shows if the actual result was higher or lower than the AI would forecast.

Income statement

. Predection Dec 31,23 Jun 30,23 Dec 31,22 Sep 30,22 Jun 30,22
totalRevenue 6.0 7M 7M 6M 3M 7M
grossProfit 5.0 6M 6M 5M 3M 7M
operatingIncome 4.0 5M 6M 4M 2M 6M
. netInterestIncome
incomeBeforeTax 5.0 5M 6M 5M 2M 6M
taxProvision
netIncome 3.0 4M 5M 4M 2M 5M
otherOperatingExpenses 1.0 2M 1M 1M 0M 1M
netIncomeApplicableToCommonShares 2M
reconciledDepreciation

Balance sheet

. Predection Dec 31,23 Jun 30,23 Dec 31,22 Sep 30,22 Jun 30,22
. itotalAssets 13.0 13M 13M 12M 12M 13M
totalCurrentAssets 11.0 12M 12M 10M 10M 12M
. cashAndShortTermInvestments 5.0 6M 6M 5M 5M 6M
. cash 5.0 6M 6M 5M 5M 6M
otherAssets 0M 0M
netWorkingCapital 11M 9M 11M
netInvestedCapital 12M 10M 12M
netDebt -7.0 -6M -6M -5M -5M -6M

Cash Flow

. Predection Dec 31,23 Jun 30,23 Dec 31,22 Sep 30,22 Jun 30,22
. totalCashFromOperatingActivities 3.0 4M 4M 4M 2M 4M
. . depreciationAndAmortization 0.0 0M 0M 0M 0M 0M
. . . changeToAccountReceivables -0.0 -0M -1M 0M 0M -1M
. . freeCashFlow 3.0 4M 4M 4M 2M 4M
. incomeTaxExpense. . 1.0 1M 1M 1M 0M 1M

``` ```